TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.4% | 41.7% | 226.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 69.5% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,363.8% | -1,156.2% | -1,509.4% | -5,160% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,422.1% | -1,201.3% | -1,571.9% | -5,384.8% |
| EPS Diluted | -0.28 | -0.28 | -0.26 | -0.3 |
| % Growth | 0% | -7.7% | 13.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |